Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sadly, if I have to educate you on this, you should not be investing in any biotech/pharma company. Under the table handshake deals that nobody knows about is clearly how the FDA works.
Haha... What reality are you living in? It would take HGEN years to get production to 10 million vials and billions of dollars. You fail to consider that U.S. hospitalizations are falling fast and will continue to do so as people get vaccinated. How could HGEN provide several million doses when it'll take 12 months just to get to 100K doses? You also fail to consider foreign countries aren't going to pay squat for a dose.
BLAHAHAHA!! HGEN would be the 23rd most valued company in the S&P 500 if that was true. Bigger than Pfizer, Merck, Abbott, Abbvie, Bristol Myers, Amgen, Intel, Coke, Exxon Mobil, Cisco, etc.
Assuming 450 million people, they would need 900 million doses (2 doses each) to get everyone vaccinated. Given the likelihood of having to take the vaccine every year, the EU appears to have secured enough doses for 2022 and 2023 (another 900 million).
Never said I did. However, longs have lost a nice chunk of change on their position from March 29's $29+ to today.
LIVE-AIR has two important limitations. First, while it demonstrated an improvement in survival in subjects with CRP<150 mg/L and aged <85, the study was not powered to observe a survival benefit, and indeed did not achieve statistical significance on this key secondary endpoint in the mITT population.
Second, the observations pertaining to benefits in the population that had CRP<150 mg/L and age <85 were exploratory.
Pretty sweeet returns for shorts... From $29+ down to $13 and change. Longs on the other hand are still down $10 from the highs. But, keep your shares tight and don't sell until $100 or $500.
It proves exactly my point that people know. And if people know, people talk. Its only natural.
Think what you want, dude. My M&A day job says I would know if HGEN was on the block and they ain't.
This is complete and utter non-sense because you have no idea what you're talking about. If HGEN was looking to sell itself, it would hire an investment bank who would prepare a CIP, make calls to a good number of potential buyers to obtain interest and start initial discussions. If initial discussions moved forward... legal teams, diligence providers, etc., are brought in. In active processes hundreds of people know about the deal and even though NDA's are signed, it doesn't stop people from talking about it which turns hundreds into thousands of people in the know. Also, if a third party reached out to HGEN with a buyout proposal, said proposal would need to be disclosed to the board and eventually to shareholders and clearly that has not happened.
What does the media have to do with anything? You act like information isn't shared that never makes it to the media. Investment banks/bankers/diligence providers, etc., all talk.
You have NO idea what you're talking about. Investment banks often purposely leak discussions to help drive additional parties to the table. Also, repercussions are only if we trade on the news or share news with others who trade on it.
Hahaha!! Hello, when you're in talks with someone people know. Lots of people know --- Executive Management teams of all parties, Investment Bankers, Lawyers, Diligence providers, Board of Directors, etc. You act like nobody talks... You clearly have never worked in the M&A world, I have for decades.
Haha... Glad you finally know what a dataroom is. I've been in thousands of them in my time. The fact that a dataroom has been "set-up" means absolutely nothing as it costs peanuts to set-one up. Cameron did NOT mention the dataroom had been populated nor did he mentioned 3rd parties were given access. BTW, datarooms are used for a lot of reasons other than M&A.
It is NOT possible for the FDA to grant approval without clinical trials and a thorough FDA review process. If it was, there wouldn't be a need for EUA.
I'll simplify it for you... No investment bankers, diligence providers, etc., have been hired by HGEN or any potential buyer to discuss a potential buyout of HGEN.
You clearly haven't been following the trend in new cases, hospitalizations, etc. in the U.S.. Everyone doesn't need to be vaccinated to reduce caseloads to a very small number which will be the case by mid-to-late Summer.
I'll take this as your way of admitting you have no way of arguing your point.
Huh? Everyone knew it was going to take time for vaccines to be rolled out and the U.S. is well ahead where anyone thought. Treatments won't be a pressing matter in the U.S. in a few weeks to a month and thus, HGEN (to the extent it gets EUA) is going to have to figure out how to get foreign countries to approve and buy its treatment. Everyone on this board keeps saying $10K per dose which is completely absurd.
The last time this data was presented, the share price went to $33+. Looks like investors are less interested in the data this time around. I wonder why...
Shorts had it easy because they knew Management was going to raise capital... They shorted it on the spike and thru the offering and have largely covered.
Nobody is going to pay $10K per treatment, not even in the U.S. The vast majority of cases are outside the U.S.. The per capita income in India is ~$2,100. Brazil's per capita income is ~$9K. And you think they are going to pay $10,000? Maybe $200 or $300.
Every drug has different production timelines (some are easy and cheap to produce others the exact opposite). Second, HGEN has no production and is spending $200+ million to get contract manufacturers to a 100K annual run-rate. Comparing PFE, MRK, etc., have massive production abilities they've invested tens of billions of dollars. Comparing them to HGEN is beyond laughable.
LIVE-AIR has two important limitations. First, while it demonstrated an improvement in survival in subjects with CRP<150 mg/L and aged < 85, the study was not powered to observe a survival benefit, and indeed did not achieve statistical significance on this key secondary endpoint in the mITT population. Second, the observations pertaining to benefits in the population that had CRP<150 mg/L and age < 85 were exploratory.
The vast majority of those cases will never see a hospital and will either result in death or full recovery before HGEN could produce a few hundred vials. Also, foreign countries don't pay anywhere near what the U.S. pays for drugs and no third world country would ever spend $10k for a dose... Try at most a few hundred dollars.
10 million vials?! Management noted it will take 12 months to get production to an annual production rate of 100K units. Clearly, you don't understand what that means.
Congratulations... Your losses are a little bit smaller after today's rally on low volume. But at least you're used to celebrating the little things in life.
Sorry you missed me... however, my deal making career keeps me more than busy most days.
You think GILD is dumb money compared to HGEN?! SMH... GILD walked... but you don't want to believe the obvious. BTW, how many CAR-T approved therapies does GILD own?
You fail to consider the importance of the two time periods... Sept/Oct/Nov 2020 vs. April 2021. The need to combat COVID last fall was immensely different than today. But, keep reading your Motley Fool.
Amazing how this board continues to think HGEN terminated a relationship with GILD. And what's funnier is you all believe Management terminating a relationship with one of bluest, blue chip biotech companies in the world is bullish. Ridiculous.
Oh... But you have a Motley Fool article, which is worth even less than a share of HGEN.
If today's news was actually bullish, HGEN wouldn't have been down another 6%. The fact y'all believe HGEN walked away from GILD related to a CAR-T therapy is beyond comical.
It's already mid-April, so common sense would say let's finish the year out the most effective way... which is doing the status quo.
There likely has been damage but mostly to the poor and kids who don't have dedicated support at home. For the vast majority of kids, they'll be able to make up for lost time over the next couple of years.
Haha... Maybe you should get the other side of the story. You know, ask the blue-chip, well-capitalized biotech firm that needs HGEN like it needs you wasting their time asking them questions.
Simply put... The hot girl (GILD) broke up with the ugly, fat guy (HGEN) when she realized he wasn't rich and didn't have any attractive assets.